Paul G. Richardson

TL;DR: This work finds pervasive DNA damage in hematologic malignancies, including multiple myeloma, lymphoma and leukemia, which leads to activation of a p53-independent, proapoptotic network centered on nuclear relocalization of ABL1 kinase, and identifies a new synthetic-lethal strategy to selectively target cancer cells presenting with endogenous DNA damage and low YAP1 levels.

TL;DR: Less severe cardiac changes were seen in patients given PL-DOX relative to historical control patients given comparable cumulative doses of doxorubicin.

TL;DR: Clinical development is ongoing to investigate bortezomib activity as monotherapy and in combination regimens for the treatment of non-Hodgkin's lymphoma, solid tumors, and early presentations of myeloma.

TL;DR: VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5 years' follow-up and despite substantial use of novel-agent-based salvage therapies, there is no emerging safety signal for second primary malignancies following VMP.

TL;DR: Targeting pDC-MM interactions as a therapeutic strategy to overcome drug resistance in MM is validates targeting toll-like receptors with CpG oligodeoxynucleotides.